Synthesis of Ac-PSMA-617 for Preclinical Use.

Background: The recent approval of radiopharmaceuticals for diagnosis and treatment of cancer is ushering nuclear medicine into a new era of theranostics and alpha therapy using radiopharmaceuticals labeled with Ac shows remarkable results in clinical trials. As such, reliable methods for the synthesis and quality control of Ac-radiopharmaceuticals are needed.

Objective: Ac-PSMA-617 is being used for targeted alpha therapy in patients with prostate cancer, and we had cause to synthesize the agent for preclinical use.